Skip to main content
Premium Trial:

Request an Annual Quote

Ariadne, OU Team Up to Offer Cancer-Related Pathway Collection

NEW YORK (GenomeWeb News) — Ariadne Genomics said today that it has partnered with the University of Oklahoma to develop a cancer-related pathways collection.
 
The collection will then become available to Ariadne customers as an add-on to its pathway-analysis product line, according to the company.
 
The University of Oklahoma has already deployed Ariadne’s Pathway Studio software tool to develop a collection of cancer-related pathways.
 
Dee Wu, associate professor at the OU Health Sciences Center, said that the university will “perform scientific evaluation of pathway expansion and microarray data analysis algorithms available in Pathway Studio” in order to “build up a collection of cancer-related pathways using its built-in ResNet database and advanced pathway reconstruction and literature mining tools.”
 
Financial details were not discussed.

Filed under

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.